This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

StemCells, Inc. CEO Discusses Interim 6-Month Data From Spinal Cord Injury Trial - Call Transcript

Stocks in this article: STEM

StemCells, Inc. (STEM)

Interim 6-Month Data from Spinal Cord Injury Trial Call

September 4, 2012 11:30 am ET

Executives

Martin M. McGlynn – President, Chief Executive Officer & Director

Armin Curt, M.D. – Professor & Chairman of the Spinal Cord Injury Center University of Zurich

Stephen Huhn, M.D., FACS, FAAP – Vice President & Head of CNS Program

Analyst

Stephen M. Dunn – LifeTech Capital

[Jason Colbert – Max M Group]



Presentation



Operator



Welcome to the StemCells, Inc. webcast on interim six month data from spinal cord injury trial. At this time all participants are in a listen only mode. We will be facilitating a question and answer session towards the end of today’s conference. (Operator Instructions) As a reminder, the conference is being recorded for replay purposes. I would now like to turn the presentation over to the host for today’s conference Mr. Martin McGlynn, Chief Executive Officer.

Martin M. McGlynn

Welcome to StemCells, Inc.’s webcast during which we will present a summary of the Phase I/II data in our chronic spinal cord injury trial which is being conducted in Balgrist Switzerland. Before we go any further I would like to introduce you to Dr. Armin Curt who is on the line on the call who is professor and chairman of the Spinal Cord Injury Center at the University of Zurich and is the medial director of the Paraplegic Center at Balgrist University Hospital and Dr. Curt is the principle investigator on this study.

Dr. Curt will make the majority of the remarks and conduct most of the presentation. He will be preceded by Dr. Stephen Huhn who is a neurosurgeon and heads our CNS Program and is the vice president of StemCells, Inc. Stephen will start off with a few introductory slides and then when Dr. Curt is finished with his presentation Stephen will wrap up on the presentation and then thereafter we will open it up to Q&A. Without any further adieu I’d like to hand you over to Dr. Stephen Huhn.

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 18,030.21 +6.04 0.03%
S&P 500 2,081.88 -0.29 -0.01%
NASDAQ 4,773.4720 +8.0480 0.17%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs